Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in patients with Non ST Elevation Acute Coronary Syndromes

• Conditions: on ST Elevation Acute Coronary Syndromes; MedDRA version: 14.1Level: PTClassification code 10051592Term: Acute coronary syndromeSystem Organ Class: 10007541 - Cardiac disorders; Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]

• Registration Number: EUCTR2012-003897-21-IT
• Lead Sponsor: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-12-28
• Last Update Posted: 11 April 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-PATIENT WITH NON-ST ELEVATION ACUTE CORONARY SYNDROMES - men aged between 50 and 80 years - postmenopausal women
Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 24
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 40

Exclusion Criteria

men aged <50 years or >80 years - impossibility to give informed consent - women of childbearing age - diabetes mellitus - severe renal failure (CrCl < 30 ml/min) - infective, neoplastic or autoimmune diseases - ACS and /or TIA/stroke in the previous three months - trauma or surgical operations in the previous three months - active hemorrhage - fibrinolytic therapy within 24 hours before randomization, - a need for oral anticoagulation therapy - an increased risk of bradycardia - drugs study hypersensitivity (including aspirin) - moderate to severe hepatic impairment 15 - co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)
GRACE RISK SCORE >140
In stent restenosis

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified